Nevertheless, only a fraction of patients responds to monotherapy; the combination of CTLA-4 and PD-1 blockers showed a remarkable increase in response rates and median survival time in melanoma and renal cell carcinoma [52,53,54]. This evidence concerns the gene CTLA4 and renal cell carcinoma.